Publications until 2011

2011 / 2010 / 2009 / 2008

2011

Review

Novel strategies for microdose studies using non-radiolabeled compounds.

Maeda K, Sugiyama Y. Adv Drug Deliv Rev. 2011;63(7):532-8.
Pubmed DOI

Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I.

Xue X, Gong LK, Maeda K, Luan Y, Qi XM, Sugiyama Y, Ren J. Mol Pharm. 2011;8(6):2183-92.
Pubmed DOI

Hepatic uptake in the dog: comparison of uptake in hepatocytes and human embryonic kidney cells expressing dog organic anion-transporting polypeptide 1B4.

Wilby AJ, Maeda K, Courtney PF, Debori Y, Webborn PJ, Kitamura Y, Kusuhara H, Riley RJ, Sugiyama Y. Drug Metab Dispos. 2011;39(12):2361-9.
Pubmed DOI

Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.

Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. J Pharmacol Exp Ther. 2011;339(3):935-44.
Pubmed DOI

Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone.

Okada R, Maeda K, Nishiyama T, Aoyama S, Tozuka Z, Hiratsuka A, Ikeda T, Kusuhara H, Sugiyama Y. Drug Metab Dispos. 2011;39(12):2290-7.
Pubmed DOI

Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.

Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, Sugiyama Y. Clin Pharmacol Ther. 2011;90(4):575-81.
Pubmed DOI

The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.

Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, Roth W, Ikushiro S, Sugiyama Y. Pharmacogenet Genomics. 2011;21(9):523-30.
Pubmed DOI

The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan.

Takashima T, Hashizume Y, Katayama Y, Murai M, Wada Y, Maeda K, Sugiyama Y, Watanabe Y. Mol Pharm. 2011;8(5):1789-98.
Pubmed DOI

Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study.

Maeda K, Takano J, Ikeda Y, Fujita T, Oyama Y, Nozawa K, Kumagai Y, Sugiyama Y. Clin Pharmacol Ther. 2011;90(2):263-70.
Pubmed DOI

Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose.

Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, Noguchi T, Yoshida K, Sugiyama Y. Pharmacogenet Genomics. 2011;21(8):495-505.
Pubmed DOI

Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes.

Kotani N, Maeda K, Watanabe T, Hiramatsu M, Gong LK, Bi YA, Takezawa T, Kusuhara H, Sugiyama Y. Drug Metab Dispos. 2011;39(9):1503-10.
Pubmed DOI

Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.

Takashima T, Yokoyama C, Mizuma H, Yamanaka H, Wada Y, Onoe K, Nagata H, Tazawa S, Doi H, Takahashi K, Morita M, Kanai M, Shibasaki M, Kusuhara H, Sugiyama Y, Onoe H, Watanabe Y. J Nucl Med. 2011;52(6):950-7.
Pubmed DOI

Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects.

Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y. Clin Pharmacol Ther. 2011;89(6):837-44.
Pubmed DOI

Ubiquitination is associated with lysosomal degradation of cell surface-resident ATP-binding cassette transporter A1 (ABCA1) through the endosomal sorting complex required for transport (ESCRT) pathway.

Mizuno T, Hayashi H, Naoi S, Sugiyama Y. Hepatology. 2011;54(2):631-43.
Pubmed DOI

Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies.

Yamane N, Tozuka Z, Kusama M, Maeda K, Ikeda T, Sugiyama Y. Pharm Res. 2011;28(8):1963-72.
Pubmed DOI

Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments.

Watanabe T, Kusuhara H, Watanabe T, Debori Y, Maeda K, Kondo T, Nakayama H, Horita S, Ogilvie BW, Parkinson A, Hu Z, Sugiyama Y. Drug Metab Dispos. 2011;39(6):1031-8.
Pubmed DOI

Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice.

Miyajima M, Kusuhara H, Fujishima M, Adachi Y, Sugiyama Y. Drug Metab Dispos. 2011;39(5):814-9.
Pubmed DOI

Calpain-mediated cleavage negatively regulates the expression level of ABCG1.

Hori N, Hayashi H, Sugiyama Y. Atherosclerosis. 2011;215(2):383-91.
Pubmed DOI

Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.

Sugiyama T, Shuto T, Suzuki S, Sato T, Koga T, Suico MA, Kusuhara H, Sugiyama Y, Cyr DM, Kai H. Biochem Biophys Res Commun. 2011;404(3):853-8.
Pubmed DOI

Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion.

Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, Sugiyama Y. Clin Pharmacol Ther. 2011;89(1):81-8.
Pubmed DOI

2010

Review

Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans.

Watanabe T, Kusuhara H, Sugiyama Y. J Pharmacokinet Pharmacodyn. 2010;37(6):575-90.
Pubmed DOI

Review

Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.

Kusuhara H, Sugiyama Y. Drug Metab Rev. 2010;42(3):539-50.
Pubmed DOI

Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects.

Tozuka Z, Kusuhara H, Nozawa K, Hamabe Y, Ikushima I, Ikeda T, Sugiyama Y. Clin Pharmacol Ther. 2010;88(6):824-30.
Pubmed DOI

The ATP-binding cassette transporter BCRP1/ABCG2 plays a pivotal role in cardiac repair after myocardial infarction via modulation of microvascular endothelial cell survival and function.

Higashikuni Y, Sainz J, Nakamura K, Takaoka M, Enomoto S, Iwata H, Sahara M, Tanaka K, Koibuchi N, Ito S, Kusuhara H, Sugiyama Y, Hirata Y, Nagai R, Sata M. Arterioscler Thromb Vasc Biol. 2010;30(11):2128-35.
Pubmed DOI

Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport.

Takashima T, Nagata H, Nakae T, Cui Y, Wada Y, Kitamura S, Doi H, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y. J Pharmacol Exp Ther. 2010;335(2):314-23.
Pubmed DOI

The use of hepatocytes to investigate drug uptake transporters.

Maeda K, Sugiyama Y. Methods Mol Biol. 2010;640:327-53.
Pubmed DOI

Direct and rapid genotyping of glutathione-S-transferase M1 and T1 from human blood specimens using the SmartAmp2 method.

Okada R, Ishizu Y, Endo R, Lezhava A, Ieiri I, Kusuhara H, Sugiyama Y, Hayashizaki Y. Drug Metab Dispos. 2010;38(10):1636-9.
Pubmed DOI

Genome-wide analysis of epigenetic signatures for kidney-specific transporters.

Kikuchi R, Yagi S, Kusuhara H, Imai S, Sugiyama Y, Shiota K. Kidney Int. 2010;78(6):569-77.
Pubmed DOI

In silico classification of major clearance pathways of drugs with their physiochemical parameters.

Kusama M, Toshimoto K, Maeda K, Hirai Y, Imai S, Chiba K, Akiyama Y, Sugiyama Y. Drug Metab Dispos. 2010;38(8):1362-70.
Pubmed DOI

Short- and medium-chain fatty acids enhance the cell surface expression and transport capacity of the bile salt export pump (BSEP/ABCB11).

Kato T, Hayashi H, Sugiyama Y. Biochim Biophys Acta. 2010;1801(9):1005-12.
Pubmed DOI

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. J Pharmacol Exp Ther. 2010;333(3):788-96.
Pubmed DOI

Basolateral efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3) facilitates intestinal absorption of folates in mouse.

Kitamura Y, Kusuhara H, Sugiyama Y. Pharm Res. 2010;27(4):665-72.
Pubmed DOI

DNA methylation profiles of organic anion transporting polypeptide 1B3 in cancer cell lines.

Ichihara S, Kikuchi R, Kusuhara H, Imai S, Maeda K, Sugiyama Y. Pharm Res. 2010;27(3):510-6.
Pubmed DOI

Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine.

Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, Horita S, Sugiyama Y. J Pharmacol Exp Ther. 2010;333(1):341-50.
Pubmed DOI

Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine.

Kitamura Y, Kusuhara H, Sugiyama Y. J Pharmacol Exp Ther. 2010;332(2):659-66.
Pubmed DOI

Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans.

Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y. Drug Metab Dispos. 2010;38(2):215-22.
Pubmed DOI

Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier.

Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, Sugiyama Y. Drug Metab Dispos. 2010;38(1):168-76.
Pubmed DOI

2009

Review

In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney.

Kusuhara H, Sugiyama Y. Drug Metab Pharmacokinet. 2009;24(1):37-52.
Pubmed

Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms.

Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I. J Clin Pharmacol. 2009;49(11):1309-17.
Pubmed DOI

Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4.

Hirouchi M, Kusuhara H, Onuki R, Ogilvie BW, Parkinson A, Sugiyama Y. Drug Metab Dispos. 2009;37(10):2103-11.
Pubmed DOI

Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments.

Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y. Drug Metab Dispos. 2009;37(7):1471-9.
Pubmed DOI

The eighth and ninth transmembrane domains in organic anion transporting polypeptide 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17beta-D-glucuronide.

Miyagawa M, Maeda K, Aoyama A, Sugiyama Y. J Pharmacol Exp Ther. 2009;329(2):551-7.
Pubmed DOI

Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients.

Yamagata T, Morishita M, Kusuhara H, Takayama K, Benameur H, Sugiyama Y. Int J Pharm. 2009;370(1-2):216-9.
Pubmed DOI

Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Kusama M, Maeda K, Chiba K, Aoyama A, Sugiyama Y. Pharm Res. 2009;26(4):822-35.
Pubmed DOI

The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine.

Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y. Drug Metab Dispos. 2009;37(3):555-9.
Pubmed DOI

Analysis of DNA methylation and histone modification profiles of liver-specific transporters.

Imai S, Kikuchi R, Kusuhara H, Yagi S, Shiota K, Sugiyama Y. Mol Pharmacol. 2009;75(3):568-76.
Pubmed DOI

Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4).

Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y. Drug Metab Dispos. 2009;37(2):315-21.
Pubmed DOI

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.

Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. J Pharmacol Exp Ther. 2009;328(2):652-62.
Pubmed DOI

Short-chain ubiquitination is associated with the degradation rate of a cell-surface-resident bile salt export pump (BSEP/ABCB11).

Hayashi H, Sugiyama Y. Mol Pharmacol. 2009;75(1):143-50.
Pubmed DOI

2008

Review

Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.

Maeda K, Sugiyama Y. Drug Metab Pharmacokinet. 2008;23(4):223-35.
Pubmed

Review

Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans.

Kitamura S, Maeda K, Sugiyama Y. Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4-6):617-28.
Pubmed DOI

Review

[Adverse effects of drugs induced by transporter-mediated tissue distribution and elimination].

Kusuhara H. Chudoku Kenkyu. 2008;21(1):13-27.
Pubmed

Molecular mechanisms of cleft lip formation in CL/Fr mice.

Nakazawa M, Matsunaga K, Asamura S, Kusuhara H, Isogai N, Muragaki Y. Scand J Plast Reconstr Surg Hand Surg. 2008;42(5):225-32.
Pubmed DOI

Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3).

Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, Sugiyama Y. J Pharmacol Exp Ther. 2008;327(2):465-73.
Pubmed DOI

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism.

Suwannakul S, Ieiri I, Kimura M, Kawabata K, Kusuhara H, Hirota T, Irie S, Sugiyama Y, Higuchi S. J Hum Genet. 2008;53(10):899-904.
Pubmed DOI

Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.

Kitamura S, Maeda K, Wang Y, Sugiyama Y. Drug Metab Dispos. 2008;36(10):2014-23.
Pubmed DOI

Evaluation of hepatic uptake clearance of tetrodotoxin in the puffer fish Takifugu rubripes.

Matsumoto T, Nagashima Y, Kusuhara H, Ishizaki S, Shimakura K, Shiomi K. Toxicon. 2008;52(2):369-74.
Pubmed DOI

Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) glucuronide, a pharmacologically active metabolite of S-8921.

Sakamoto S, Kusuhara H, Horie K, Takahashi K, Baba T, Ishizaki J, Sugiyama Y. Drug Metab Dispos. 2008;36(8):1553-61.
Pubmed DOI

Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats.

Levy JK, Crawford PC, Kusuhara H, Motokawa K, Gemma T, Watanabe R, Arai S, Bienzle D, Hohdatsu T. J Vet Intern Med. 2008;22(2):330-4.
Pubmed DOI

Pharmacokinetics of tetrodotoxin in puffer fish Takifugu rubripes by a single administration technique.

Matsumoto T, Nagashima Y, Kusuhara H, Ishizaki S, Shimakura K, Shiomi K. Toxicon. 2008;51(6):1051-9.
Pubmed DOI

Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.

Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. Drug Metab Dispos. 2008;36(6):995-1002.
Pubmed DOI

Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.

Kitamura Y, Koto H, Matsuura S, Kawabata T, Tsuchiya H, Kusuhara H, Tsujimoto H, Sugiyama Y. Drug Metab Dispos. 2008;36(5):807-10.
Pubmed DOI

Involvement of multiple efflux transporters in hepatic disposition of fexofenadine.

Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y. Mol Pharmacol. 2008;73(5):1474-83.
Pubmed DOI

Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans.

Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Drug Metab Dispos. 2008;36(4):663-9.
Pubmed DOI

Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.

Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, Roth W, Igarashi T, Sugiyama Y. Drug Metab Dispos. 2008;36(4):796-805.
Pubmed DOI

Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.

Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y. Clin Pharmacol Ther. 2008;84(1):95-103.
Pubmed DOI

P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.

Ose A, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T, Yamamoto A, Sugiyama Y. Drug Metab Dispos. 2008;36(2):427-34.
Pubmed DOI

Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta.

Saji T, Kikuchi R, Kusuhara H, Kim I, Gonzalez FJ, Sugiyama Y. J Pharmacol Exp Ther. 2008;324(2):784-90.
Pubmed DOI